Cardiff Oncology(CRDF) - 2024 Q1 - Quarterly Results

Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update - In RAS wild-type mCRC, preclinical data presented at AACR demonstrated onvansertib's antitumor activity both as a single agent and in combination, highlighting its broad activity across all mCRC - - Cash and equivalents of $67 million as of March 31, 2024, projected runway into Q3 2025 - SAN DIEGO, May 2, 2024 -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develo ...